Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

A container with vaccine bottles lined up next to each other

Monday Morning Vaccine Breakthrough: Terrific News for the West, but in LMICs Terms and Conditions Apply

This morning, America (and much of the world) woke up to a snippet of terrific news: Pfizer and BioNTech announced their SARS-CoV2 vaccine candidate showed 90 percent efficacy. But for policymakers in low- and middle-income countries, today’s news offers limited cause for celebration—and the Pfizer/BioNTech results may even lengthen the timeline for eventual LMIC access.

The Race for a COVID-19 Vaccine: An Overview of Current Proposals and Our Contribution in Bringing in the Missing Middle

Much rests with the successful development and introduction of an effective COVID-19 vaccine. It may be our only path towards fully reopening our economies without fear of future outbreaks and associated health and economic impacts. See here for an overview of recent vaccine initiatives. 

Graphic explaining MVAC process

A Final MVAC Blueprint—and the Start of an R&D Revolution?

Despite decades of investment, TB remains a global crisis. Each year, TB kills 1.6 million people—making it the world’s deadliest infectious diseases. We have set out to develop a solution: what we ultimately called the Market-Driven, Value-Based Advance Commitment (MVAC), a mechanism to create and guarantee a market for better TB treatment, if and when such a treatment becomes available.

Pages